681 Participants Needed

Online Platforms for Alzheimer's Disease Information Delivery

(eSMARTER Trial)

Recruiting at 1 trial location
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Banner Health
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I need to stop my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment eHealth Platform, Videoconference Telehealth Platform for Alzheimer's Disease?

Research shows that eHealth platforms, like the Digital Alzheimer Center, can improve the quality of dementia care by providing disease information and connecting patients and caregivers with health professionals. Videoconferencing has been found to save time and enhance communication among healthcare providers, which is beneficial for managing complex cases in Alzheimer's care.12345

Is it safe to use online platforms for delivering Alzheimer's disease information?

The research does not provide specific safety data for online platforms used for Alzheimer's disease information delivery, but it discusses the use of electronic systems to improve patient safety in general.678910

How does the Online Platforms for Alzheimer's Disease Information Delivery treatment differ from other treatments for Alzheimer's?

This treatment is unique because it uses online platforms like eHealth and videoconference telehealth to provide information and support for Alzheimer's patients and their caregivers. Unlike traditional treatments, it focuses on improving knowledge, communication, and care coordination through digital means, which can save time and enhance multidisciplinary exchanges.123511

What is the purpose of this trial?

This randomized non-inferiority study will evaluate self-directed scalable electronic health platform (eHealth) methods for communicating Alzheimer's gene and biomarker results compared to videoconference telehealth disclosure with healthcare providers, as well as characterize the impacts of learning this information on the participant.

Research Team

JL

Jessica Langbaum, PhD

Principal Investigator

Banner Alzheimer's Institute

Eligibility Criteria

This trial is for individuals who can follow the study's procedures, are fluent in English, willing to have their blood drawn for future testing, and have internet access with a device. They must understand the consent form content to participate.

Inclusion Criteria

I have access to the internet and a device that can connect to it.
I understand the consent form as proven by correctly answering questions about it.
I can read, write, and speak English fluently.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
Remote eligibility confirmation

Pre-disclosure Education

Participants use eHealth platforms (ADWebPortal or ADChatbot) for pre-disclosure education

1-2 weeks
Self-directed online sessions

Disclosure

Participants receive Alzheimer's gene and biomarker results via eHealth platform or telehealth videoconference

1 week
1 virtual visit (telehealth or eHealth)

Follow-up

Participants are monitored for psychological and cognitive impacts post-disclosure

6 months
Remote assessments at 0-7 days, 6 weeks, and 6 months

Treatment Details

Interventions

  • eHealth Platform
  • Videoconference Telehealth Platform
Trial Overview The study compares two methods of communicating Alzheimer's gene and biomarker results: an eHealth platform where participants learn on their own versus a videoconference telehealth session with healthcare providers.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: eHealth platformExperimental Treatment1 Intervention
The eHealth platform consists of the self-directed web-portal (ADWebPortal) and chatbot (ADChatbot) to receive their Alzheimer's-related test results. Participants randomized to this arm can switch between the two or schedule a virtual appointment with a healthcare provider.
Group II: Videoconference telehealthActive Control1 Intervention
The videoconference telehealth platform consists of remote visit(s) with a healthcare provider to receive their Alzheimer's-related test results.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Banner Health

Lead Sponsor

Trials
26
Recruited
1,006,000+

National Institute on Aging (NIA)

Collaborator

Trials
1,841
Recruited
28,150,000+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Findings from Research

The Digital Alzheimer Center (DAC) was found to be generally useful for patients with dementia and their carers, with 65% of patients and 78% of carers appreciating its information and support features.
Despite its usefulness, only a minority of patients (33%) found the portal easy to learn, highlighting the need for better design and ongoing usability testing to improve user experience.
Evaluation of the Digital Alzheimer Center: Testing Usability and Usefulness of an Online Portal for Patients with Dementia and Their Carers.Hattink, B., Droes, RM., Sikkes, S., et al.[2022]
There is a significant need for smartphone-based interventions to support caregivers of the 5.4 million people with Alzheimer's disease, as current apps available for caregivers have limited functions and do not adequately address their complex needs.
Research indicates that there is a lack of tailored caregiving apps for Hispanic populations, highlighting a gap in accessibility and support for diverse caregiver communities.
Smartphone-Based Health Technologies for Dementia Care: Opportunities, Challenges, and Current Practices.Brown, EL., Ruggiano, N., Li, J., et al.[2020]
The 'Improvehealth.eu' eHealth service was successfully implemented in a pilot study with 46 patients, showing a significant improvement in medication adherence for those using the intervention (odds ratio = 10.0, P = .03).
Patients using the eHealth service reported feeling more engaged and in control of their treatment, with 81% expressing positive perceptions, suggesting the intervention has potential to enhance treatment outcomes for depressive disorders.
Feasibility of an eHealth service to support collaborative depression care: results of a pilot study.Meglic, M., Furlan, M., Kuzmanic, M., et al.[2021]

References

Evaluation of the Digital Alzheimer Center: Testing Usability and Usefulness of an Online Portal for Patients with Dementia and Their Carers. [2022]
[The use of videoconferencing in psychogeriatrics, a pilot experiment]. [2021]
Smartphone-Based Health Technologies for Dementia Care: Opportunities, Challenges, and Current Practices. [2020]
Feasibility of an eHealth service to support collaborative depression care: results of a pilot study. [2021]
Caregiver Response to an Online Dementia and Caregiver Wellness Education Platform. [2022]
Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting. [2019]
Using a patient internet portal to prevent adverse drug events: a randomized, controlled trial. [2018]
[Adverse drug events in patients hospitalized in internal medicine]. [2013]
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies. [2021]
Improvement of medication event interventions through use of an electronic database. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
The development of an Alzheimer's disease channel for the Michigan Interactive Health Kiosk Project. [2006]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security